Healthcare Active Runners: Pfizer Inc. (NYSE:PFE), Gilead Sciences (NASDAQ:GILD), Johnson & Johnson (NYSE:JNJ), Merck & Co (NYSE:MRK)

Pfizer Inc. (NYSE:PFE) invites investors and the general public to view and listen to a webcast of a conference call with investment analysts at 10 a.m. EDT on Monday, May 5, 2014. Pfizer Inc. (NYSE:PFE) stock performance was 1.05% in last session and finished the day at $31.82. Traded volume was 21.09million shares in the last session and the average volume of the stock remained 26.39million shares. The beta of the stock remained 0.66. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

In a time when medical costs seem to be soaring in the U.S., we have yet another drug that has been priced superficially at $1000 a pill or roughly $84,000 for a 12 week course and is under scrutiny. The drug in question here is Sovaldi, which is being touted to tackle hepatitis C, a chronic disease that is widespread and affects over 3 million people in the entire country. Writing a letter to Gilead Sciences, Inc. (NASDAQ:GILD)’s Chief Executive John C. Martin, two Democratic lawmakers have asked to explain the reason, behind the exorbitant pricing of the drug. Gilead Sciences Inc. (NASDAQ:GILD) rose 1.25 percent to $73.09 Tuesday on volume of 19.14million shares. The intra-day range of the stock was $71.90 to $74.30.Gilead Sciences Inc. (NASDAQ:GILD) has a market capitalization of $112.02billion.

New findings presented for the first time at the 2014 Annual Meeting of the American Academy of Dermatology (AAD) showed up to 86% of patients with moderate to severe plaque psoriasis receiving guselkumab (CNTO 1959) achieved a Physician’s Global Assessment (PGA) score of cleared or minimal at week 16, the study’s primary endpoint, US health care giant Johnson & Johnson (NYSE:JNJ) Janssen unit has said. Johnson & Johnson (NYSE:JNJ)’s stock on Mar 25, 2014 reported a increase of 2.29% to the closing price of $97.38. Its fifty two weeks range is $77.19 -$95.93. The total market capitalization recorded $274.61billion. The overall volume in the last trading session was 14.15million shares. In its share capital, JNJ has 2.82million outstanding shares.

Merck & Co. Inc (NYSE: MRK) continues to bounce around. After shares slipped more than 1% yesterday, they have popped back up 2.70% to $55.23 in a 52-week range of $43.77 to $57.65. There is a report that Sanofi (NYSE: SFY) may join the line of potential buyers for Merck’s consumer health business. On Tuesday, shares of Merck & Co. Inc. (NYSE:MRK) advanced 2.62% to close the day at $55.19. Company return on investment (ROI) is 6.60% and its monthly performance is recorded as -0.99%. Merck & Co. Inc. (NYSE:MRK) quarterly revenue growth is 12.77%.

Signup for free to be the first to receive exclusive free links. Now in your mailbox!
Join over 15,000 subscribers
Send me links

Your information will not be shared to anyone